click below
click below
Normal Size Small Size show me how
Pain/Heme/Onc 1-3
BDK
| Pharmacologic Category | Generic Name | Brand Name | Common Indication | Key Side Effects | USBW |
|---|---|---|---|---|---|
| Opioid analgesic | fentanyl CS-II | Transdermal: Duragesic: IV: Sublimaze | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritus, respiratory depression (dose-related) | potential for medication errors when converting between dosage forms; use with CYP3A4 inhibitors (or stopping CYP3A4 inducers) can increase concentrations; avoid exposing transdermal patch to external heat |
| Opioid analgesic | hydromorphone CS-II | Dilaudid | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritus, respiratory depression (dose-related) | risk of medication errors w/ high potency, use in opioid-tolerant patients only |
| Opioid analgesic | morphine (extended release) CS-II | MS Contin, Kadian | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritus, respiratory depression (dose-related) | coingestion w/ alcohol may result in potentially fatal overdose |
| Opioid analgesic | morphine (intermediate release) CS-II | IV: Duramorph, Infumorph | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritus, respiratory depression (dose-related) | risks of addiction, misuse, overdose, fatal respiratory depression, neonatal withdrawal, severe withdrawal if stopped abruptly, and dangerous sedation when combined with benzodiazepines, alcohol, or other CNS depressants. |
| Opioid analgesic | oxycodone CS-II | OxyContin, Roxicodone | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritus, respiratory depression (dose-related) | use w/ CYP3A4 inhibitors (or stopping CYP3A4 inducers) can increase concentrations |
| Opioid analgesic | methadone CS-II | Dolophine | Opioid use disorder, severe chronic pain | dizziness, drowsiness, nausea, vomiting, constipation, respiratory depression (dose-related), QTc prolongation | QTc prolongation and serious arrhythmia (Torsades de Pointes) have occurred during treatment; concomitant use w/ CYP3A4, 2B6, 2C19, or 2D6 (or stopping the same inducers) can increase concentrations |
| Analgesic (non-opioid), antipyretic | acetaminophen | PO/PR: Tylenol; IV: Ofirmev | Pain, fever | nausea, vomiting, increased hepatic transaminases | total daily dose from all sources should not exceed maximum daily limit; hepatotoxicity |
| Central analgesic; partial opioid agonist | tramadol CS-IV | Ultram, Ultram ER | Pain | dizziness, drowsiness, nausea, vomiting, constipation, respiratory depression (dose-related) | risks of addiction, misuse, overdose, fatal respiratory depression, neonatal withdrawal, severe withdrawal if stopped abruptly, and dangerous sedation when combined with benzodiazepines, alcohol, or other CNS depressants., ON: lower seizure threshold |
| Opioid and nonopioid analgesic combination | hydrocodone and acetaminophen CS-II | Lortab, Vicodin, Norco | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritis, respiratory depression (dose-related) | use w/ CYP3A4 inhibitors (or stopping CYP3A4 inducers) can increase oxycodone concentrations; hepatotoxicity |
| Opioid and nonopioid analgesic combination | oxycodone and acetaminophen CS-II | Percocet, Endocet, Roxicet | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritis, respiratory depression (dose-related) | use w/ CYP3A4 inhibitors (or stopping CYP3A4 inducers) can increase oxycodone concentrations; hepatotoxicity |
| Opioid and nonopioid analgesic combination | codeine and acetaminophen CS-III | Tylenol with Codeine #3, Tylenol with Codeine #4 | Pain | dizziness, drowsiness, nausea, vomiting, constipation, pruritis, respiratory depression (dose-related) | concomitant use or discontinuation of CYP3A4 inducers, 3A4 or 2D6 inhibitors requires careful consideration; respiratory depression and death in children after tonsillectomy or adenoidectomy who are ultra-rapid metabolizers of codeine; hepatotoxicity |
| Opioid antagonist | naloxone | Narcan, Narcan Spray (OTC), Zimhi | Opioid overdose | opioid withdrawal syndrome opioid-dependent populations, pain | --- |
| Partial opioid agonist and opioid antagonist | buprenorphine and naloxone CS-III | Suboxone | Opioid use disorder | opioid withdrawal syndrome in opioid-dependent populations, constipation, headache, diaphoresis | ON: potentially life-threatening respiratory depression (when combined w/ other CNS and respiratory depressants); addition of naloxone to buprenorphine reduces the possibility of parenteral misuse by producing opioid withdrawal syndromes when injected |
| Antimetabolite (folic acid antagonist) | methotrexate | Trexall | RA, Crohn's Disease, psoriasis, various hematologic and solid tumors | stomatitis, diarrhea, nausea, vomiting, thrombocytopenia, leukopenia, increased hepatic transaminases, pulmonary fibrosis (rare) | serious toxic rxns, fetal death/abnormalities, severe bone marrow suppression, aplastic anemia, toxicity w/ NSAIDS, may cause hepatotoxicity, lung disease, severe GI toxicity ON: use folic acid supplements to reduce side effects |
| Aromatase inhibitor | anastrozole | Arimidex | Hormone receptor positive breast cancer | fatigue, rash, flushing, hot flashes, arthralgia, nausea, vomiting, hypertension, peripheral edema, osteoporosis | ON: cardiovascular effects (hypercholesterolemia, CAD); fetal toxicity (CI in pregnancy) |
| Iron supplement | ferrous sulfate | FeroSul, SlowFe | Iron deficiency anemia | nausea, stomach upset, constipation dose-related), dark and tarry stools | accidental overdose of iron is leading cause of fatal poisoning in children <6yo |
| Water-soluble vitamin | cyanocobalamin (vitamin B12) OTC | --- | Vitamin B12 deficiency (manifests as macrocytic anemia) | no major side effects | --- |
| Water- soluble vitamin | folic acid OTC | --- | Folic acid deficiency (manifests as macrocytic anemia) prevention of neural tube defects in pregnancy | no major side effects | --- |
| Antineoplastic agent, anthracycline | doxorubicin | Adriamycin | Adjuvant therapy for breast cancer, various cancers | cardiomyopathy, alopecia, nausea, vomiting, bone marrow suppression | may cause secondary malignancies, extravasation can result in severe local tissue injury and necrosis. ON: may cause red discoloration of urine, tears, sweat, and saliva |
| Antineoplastic agent, platinum -based compound | cisplatin | Kemoplat | Advanced bladder, ovarian, and testicular cancer; various cancers | bone marrow suppression, nausea, vomiting, nephrotoxicity, neurotoxicity, ototoxicity | may cause severe myelosuppression, nausea and vomiting, renal toxicity, and dose-related neuropathy |
| Antineoplastic agent, monoclonal antibody | pembrolizumab | Keytruda | Various cancers | peripheral edema, pruritis, skin rash, endocrine and metabolic abnormalities, constipation, N/V/D, hematuria, anemia, increased liver enzymes, fatigue, musculoskeletal pain, increased serum creatinine, dyspnea | --- |
| Selective estrogen receptor modulator (SERM) | tamoxifen | Soltamox | Hormone receptor-positive breast cancer | hot flashes/ night sweats, vaginal bleeding/discharge, decreased bone density (in premenopausal females) | increased risk for uterine or endometrial cancer and thromboembolic events; ON: contraception should be used in premenopausal females due to teratogenicity of the drug; do not use w/ warfarin or h/o DVT/PE |